[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mitochondrial-biomarkers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mitochondrial-biomarkers":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,58],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":36,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":4},"100638958","immune-mitochondrial-correction-in-military-recruits-100638958",false,"NCT07622147","Immune-Mitochondrial Correction in Military Recruits","A Parallel-Group, Participant-Blinded Comparative Trial of an Immuno-Mitochondrial Correction Strategy (Sodium Nucleinate + Magnesium\u002FPyridoxine + Vitamin D3 5000 IU) Versus Standard Multivitamin Prophylaxis to Reduce Respiratory Infection Incidence in Male Military Recruits During the 6-Month Adaptation Period","IMMU-MITO","Inclusion Criteria:\n\n* Male military recruits aged 18-27 years\n* Starting initial military training at the Military Clinical Hospital of the Ministry of Defense of the Republic of Kazakhstan (Almaty)\n* Signed informed consent\n* No acute infectious diseases at enrollment\n* Willingness to comply with the study protocol for 6 months\n* Absence of any exclusion criteria\n\nExclusion Criteria:\n\n* Chronic immunodeficiency states (HIV infection, congenital immunodeficiencies, current immunosuppressive therapy)\n* Severe chronic diseases in decompensation stage (diabetes mellitus, renal failure, hepatic failure, heart failure)\n* Allergy or hypersensitivity to any components of the study interventions (multivitamin, sodium nucleinate, magnesium, vitamin B6, vitamin D)\n* Use of vitamin-mineral complexes or immunomodulators within the last 3 months prior to enrollment\n* Hypercalcemia (serum calcium \\>2.6 mmol\u002FL) or history of urolithiasis\n* Hypermagnesemia (serum magnesium \\>1.1 mmol\u002FL)\n* Sarcoidosis or other granulomatous diseases\n* Refusal or inability to provide informed consent",true,"MALE","18 Years","27 Years",{"count":22,"type":23},200,"ESTIMATED","INTERVENTIONAL",[26],"NA","The goal of this clinical trial is to learn if a new immune-mitochondrial correction strategy works better than standard vitamins to prevent infections in young male military recruits during their first 6 months of service.\n\nThe main questions it aims to answer are:\n\n1. Does the new strategy lower the number of recruits who get infections (like colds, flu, or pneumonia) over 6 months?\n2. Does the new strategy improve how well the immune cells work, specifically their mitochondria (the power source inside cells)?\n\nResearchers will compare:\n\n* Control group (100 participants): Standard multivitamin taken once a day for 30 days\n* Experimental group (100 participants): New strategy (sodium nucleinate, magnesium, vitamin B6, and vitamin D 5000 IU) taken as 3 tablets once a day for 30 days to see if the new strategy lowers infection rates more than standard vitamins.\n\nWho can take part:\n\nHealthy male military recruits aged 18-27 years who are starting their initial training at the Military Clinical Hospital in Almaty, Kazakhstan.\n\nWhat participants will do:\n\nParticipants will be placed into one of the two groups by chance (like flipping a coin). They will:\n\n* Take study pills once a day for 30 days\n* Have blood draws 3 times over 6 months (baseline, 1 month, and 6 months)\n* Have daily health checks by medical staff\n* Complete quality of life questionnaires\n\nWhat we will measure:\n\n* Number of participants who get infections during 6 months\n* How well the mitochondria in immune cells work (from blood samples)\n* Immune system status\n* Stress and adaptation levels\n* Vitamin D and other blood markers\n\nRisks and benefits:\n\nThe risks are very low. Participants may have mild discomfort or a small bruise from blood draws. All study pills are approved and registered in Kazakhstan.\n\nThere is no direct benefit to participants, but they will receive extra medical monitoring. The indirect benefit is helping develop a better prevention program to protect future recruits.\n\nWhere the study is taking place:\n\nMilitary Clinical Hospital of the Ministry of Defense of the Republic of Kazakhstan, Almaty, Kazakhstan.\n\nStudy duration:\n\nJanuary 2027 to December 2028.",[29,30,31,32,33,34,35],"Respiratory Tract Infections (RTI)","Meningitis","Primary Prevention\u002FMethods","Primary Prevention","Mitochondrial Biomarkers","Immuno-monitoring","Immuno-modulation",[37,38,39,40,41,42,43,44,45],"Military recruits","Infection prevention","Immunocorrection","Mitochondrial function","Sodium nucleinate","Vitamin D","Respiratory infections","Stress adaptation","Randomized controlled trial","NOT_YET_RECRUITING","2026-06-24",{"date":49,"type":50},"2026-06-29","ACTUAL",{"date":52,"type":23},"2027-01-01",{"date":54,"type":23},"2028-12",{"name":56,"class":57},"MIPO Clinic","OTHER",{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":4,"eligibilityCriteria":63,"healthyVolunteers":17,"sex":64,"minAge":65,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":68,"phases":4,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":87},"100581626","development-of-biomarkers-for-monitoring-menopause-in-women-100581626","NCT06852755","Development of Biomarkers for Monitoring Menopause in Women","Inclusion Criteria:\n\n* Biological female, age order than 20 years old.\n\nExclusion Criteria:\n\n* Person with cancer.\n* Person with any known acute or chronic infection.\n* Person with known chronic illness under follow up or treatment.\n* Pregnancy, one year withing delivery, under breast feeding, or three months within breast feeding.\n* Under any female horemone therapy.","FEMALE","20 Years",{"count":67,"type":23},100,"OBSERVATIONAL","This cross-sectional study aims to develop and validate mitochondrial biomarkers for monitoring menopause in women. The study will involve 100 participants divided into three groups: reproductive period, perimenopausal transition period, and postmenopausal period. Peripheral blood samples will be collected, and mitochondrial quality and quantity will be assessed using both qualitative and quantitative analyses. The study will identify potential biomarkers through metabolomics and validate them for monitoring the perimenopausal transition, providing a novel approach for women's health management during menopause.",[71,33],"Perimenopausal Biomarkers",[73,74,75,76],"Perimenopausal Transition","Mitochondria","Biomarker","Women's Health","RECRUITING","2025-05-20",{"date":80,"type":50},"2025-05-25",{"date":82,"type":50},"2024-07-30",{"date":84,"type":23},"2026-08",{"name":86,"class":57},"Fu Jen Catholic University Hospital",1]